

**1 PATIENT INFORMATION:**

Name: \_\_\_\_\_  
 Address: \_\_\_\_\_  
 City: \_\_\_\_\_ State: \_\_\_\_ Zip: \_\_\_\_\_  
 Phone: \_\_\_\_\_ Alt. Phone: \_\_\_\_\_  
 Email: \_\_\_\_\_  
 DOB: \_\_\_\_\_ Gender:  M  F Caregiver: \_\_\_\_\_  
 Height: \_\_\_\_\_ Weight: \_\_\_\_\_ Allergies: \_\_\_\_\_

**2 PRESCRIBER INFORMATION:**

Name: \_\_\_\_\_  
 Address: \_\_\_\_\_  
 City: \_\_\_\_\_ State: \_\_\_\_ Zip: \_\_\_\_\_  
 Phone: \_\_\_\_\_ Fax: \_\_\_\_\_  
 NPI: \_\_\_\_\_ DEA: \_\_\_\_\_  
 Tax I.D.: \_\_\_\_\_  
 Office Contact: \_\_\_\_\_ Phone: \_\_\_\_\_

**3 STATEMENT OF MEDICAL NECESSITY: (Please Attach All Medical Documentation)**

Date of Diagnosis: \_\_\_\_\_ ICD-10: \_\_\_\_\_  Adult Female Not of Reproductive Potential  
 Other: \_\_\_\_\_ BSA: \_\_\_\_\_ m<sup>2</sup>  Adult Male Not of Reproductive Potential

**Prior Failed Therapies:**

**Reason for Discontinuation:**

**Date:**

- |          |       |       |
|----------|-------|-------|
| 1. _____ | _____ | _____ |
| 2. _____ | _____ | _____ |
| 3. _____ | _____ | _____ |
| 4. _____ | _____ | _____ |

**If Prior Authorization is denied, recommended formulary alternatives will be provided to the prescriber based upon the patient's insurance coverage.**

**4 INJECTION TRAINING:**  To Be Administered by Pharmacist  Pharmacist to Provide Training  Patient Trained in MD Office  Manufacturer Nurse Support

**5 PICK UP OR DELIVERY:**  Delivery to Patient's Home  Delivery to Physician's Office  Pharmacy to Coordinate

**6 INSURANCE INFORMATION:** Please Include Front and Back Copies of Pharmacy and Medical Card

**PRESCRIPTION INFORMATION:**

Patient Name: \_\_\_\_\_ Patient's Date of Birth: \_\_\_\_\_

Medication	Dosage & Strength	Direction	QTY	Refills
<input type="checkbox"/> AFINITOR®				
<input type="checkbox"/> FEMARA®				
<input type="checkbox"/> GLEEVEC®				
<input type="checkbox"/> HYCAMTIN®				
<input type="checkbox"/> KISQALI®				
<input type="checkbox"/> KISQALI® FEMARA® Co-Pack				
<input type="checkbox"/> RYDAPT®				
<input type="checkbox"/> SPRYCEL®				
<input type="checkbox"/> TARGRETIN®				
<input type="checkbox"/> TASIGNA®				
<input type="checkbox"/> TEMODAR®				
<input type="checkbox"/> XELODA®				
<input type="checkbox"/> ZOLINZA®				
<input type="checkbox"/> ZYTIGA®				
<input type="checkbox"/> OTHER _____				

Supportive Medications	Dosage & Direction	QTY	Refills
<input type="checkbox"/> Aranesp® <input type="checkbox"/> Emend® <input type="checkbox"/> Neupogen® <input type="checkbox"/> Sancuso® <input type="checkbox"/> Arixtra® <input type="checkbox"/> Granix® <input type="checkbox"/> Nplate® <input type="checkbox"/> Xgeva® <input type="checkbox"/> Caphosol® <input type="checkbox"/> Lovenox® <input type="checkbox"/> Procrit® <input type="checkbox"/> Zofran® <input type="checkbox"/> Creon® <input type="checkbox"/> Neulasta® <input type="checkbox"/> Promacta®			

**PRESCRIBER SIGNATURE:** I authorize pharmacy to act as my designee for initiating and coordinating insurance prior authorizations, nursing services and patient assistance programs.

Signature: \_\_\_\_\_ Date: \_\_\_\_\_ Signature: \_\_\_\_\_ Date: \_\_\_\_\_

**Substitution Permitted**

**Dispense As Written**

Prior authorization approval and insurance benefits will be determined by the payor based upon the patient's eligibility, medical necessity, and the terms of the patient's coverage, among other things. Participation in this program is not a guarantee of prior authorization or of payment.

Confidentiality Notice: This fax is intended to be delivered only to the named addressee and contains confidential information that may be protected health information under federal and state laws. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please inform the sender immediately if you have received this document in error and then destroy this document immediately.